Clinical Trial Update: Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of celecoxib (Celebrex) in patients with recurrent respiratory papillomatosis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Papillomatosis

Drugs mentioned

• CELEBREX (Celecoxib)

Snippet

Sponsor: Northwell Health | Conditions: Recurrent Respiratory Papillomatosis | Phase 2 | Status: COMPLETED | Results posted: 2017-02-23